Alliancebernstein L.P. Atea Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 119,220 shares of AVIR stock, worth $386,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares

119,220

Previous 119,220 -0.0%

Holding current value

$386,272

Previous $394,000 1.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $4.04 $9,268 - $11,312	2,800 Added 2.41%	119,220 $394,000
Q1 2024 May 14, 2024	SELL	$3.09 - $4.56 $13,317 - $19,653	-4,310 Reduced 3.57%	116,420 $470,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $10,892 - $13,031	-3,890 Reduced 3.12%	120,730 $368,000
Q2 2023 Aug 15, 2023	BUY	$3.21 - $5.06 $112,735 - $177,707	35,120 Added 39.24%	124,620 $466,000
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $12,600 - $20,874	4,200 Added 4.92%	89,500 $299,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $22,619 - $32,084	5,200 Added 6.49%	85,300 $410,000
Q1 2022 May 13, 2022	BUY	$5.5 - $9.19 $1,100 - $1,838	200 Added 0.25%	80,100 $578,000
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $125,695 - $730,740	-16,388 Reduced 17.02%	79,900 $714,000
Q3 2021 Nov 10, 2021	BUY	$21.33 - $35.06 $138,389 - $227,469	6,488 Added 7.22%	96,288 $3.38 Million
Q2 2021 Jul 30, 2021	BUY	$19.22 - $59.08 $1.36 Million - $4.19 Million	70,998 Added 377.61%	89,800 $1.93 Million
Q1 2021 May 06, 2021	BUY	$41.42 - $88.44 $252,744 - $539,660	6,102 Added 48.05%	18,802 $1.16 Million
Q4 2020 Feb 08, 2021	BUY	$26.36 - $41.78 $334,772 - $530,606	12,700 New	12,700 $531,000

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Atea Pharmaceuticals, Inc. Transaction History